SCI REP:LINC00152的过度表达与患者生存率不佳相关,并且敲低LINC00152会损害肺癌细胞增殖

2017-06-07 MedSci MedSci原创

我们对从3个独立队列中筛选的461例肺腺癌和156例正常肺组织,进行RNA测序分析,以揭示肺癌中的异常调节的lncRNA。我们发现,与和其相邻的正常组织相比,LINC00152在肺肿瘤严重的过度表达。我们的研究表明LINC00152在肺肿瘤生长中起重要作用,并且是一种潜在的诊断/预后标志物。LINC00152在靶蛋白调控中的进一步表征可能为肺癌提供了新的治疗靶点。

我们对从3个独立队列中筛选的461例肺腺癌和156例正常肺组织,进行RNA测序分析,以揭示肺癌中的异常调节的lncRNA。我们发现,与和其相邻的正常组织相比,LINC00152在肺肿瘤严重的过度表达。具有较高LINC00152表达的患者表现出比那些表达低的患者显着更差的存活率。我们利用定量RT-PCR技术,在独立的肺组织队列中,验证了LINC00152的表达对诊断/预后的潜力。在利用siRNA在肺癌细胞系中敲低LINC00152后,细胞增殖和集落形成都减少。细胞分级和qRT-PCR分析表明,LINC00152主要在细胞质中。用曲古抑菌素A处理的细胞系中,LINC00152表达降低,表明组蛋白乙酰化可能是NSCLC中LINC00152过表达的一种机制。蛋白质印迹分析显示在LINC00152 siRNA处理后,p38a,STAT1,STAT3,CREB1,CCNE1和c-MYC蛋白表达均降低。我们的研究表明LINC00152在肺肿瘤生长中起重要作用,并且是一种潜在的诊断/预后标志物。LINC00152在靶蛋白调控中的进一步表征可能为肺癌提供了新的治疗靶点。

原文出处:

Shumei FengDavid G. Beer2,Guoan Chen,et al.Overexpression of LINC00152 correlates with poor patient survival and knockdown impairs cell proliferation in lung cancer.[J]Scientific Reports.2017 June 7.DOI:10.1038/s41598-017-03043-x.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2069802, encodeId=df662069802fc, content=<a href='/topic/show?id=904282239db' target=_blank style='color:#2F92EE;'>#肺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82239, encryptionId=904282239db, topicName=肺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Sun Nov 26 14:11:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932576, encodeId=fbe219325e6a9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Sep 15 03:11:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701027, encodeId=b1371e01027c7, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Wed May 09 13:11:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252265, encodeId=337c12522659f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256572, encodeId=c95c12565e205, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540891, encodeId=6ea6154089122, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2069802, encodeId=df662069802fc, content=<a href='/topic/show?id=904282239db' target=_blank style='color:#2F92EE;'>#肺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82239, encryptionId=904282239db, topicName=肺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Sun Nov 26 14:11:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932576, encodeId=fbe219325e6a9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Sep 15 03:11:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701027, encodeId=b1371e01027c7, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Wed May 09 13:11:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252265, encodeId=337c12522659f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256572, encodeId=c95c12565e205, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540891, encodeId=6ea6154089122, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2069802, encodeId=df662069802fc, content=<a href='/topic/show?id=904282239db' target=_blank style='color:#2F92EE;'>#肺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82239, encryptionId=904282239db, topicName=肺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Sun Nov 26 14:11:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932576, encodeId=fbe219325e6a9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Sep 15 03:11:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701027, encodeId=b1371e01027c7, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Wed May 09 13:11:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252265, encodeId=337c12522659f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256572, encodeId=c95c12565e205, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540891, encodeId=6ea6154089122, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2069802, encodeId=df662069802fc, content=<a href='/topic/show?id=904282239db' target=_blank style='color:#2F92EE;'>#肺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82239, encryptionId=904282239db, topicName=肺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Sun Nov 26 14:11:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932576, encodeId=fbe219325e6a9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Sep 15 03:11:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701027, encodeId=b1371e01027c7, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Wed May 09 13:11:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252265, encodeId=337c12522659f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256572, encodeId=c95c12565e205, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540891, encodeId=6ea6154089122, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
    2017-06-09 yxch36
  5. [GetPortalCommentsPageByObjectIdResponse(id=2069802, encodeId=df662069802fc, content=<a href='/topic/show?id=904282239db' target=_blank style='color:#2F92EE;'>#肺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82239, encryptionId=904282239db, topicName=肺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Sun Nov 26 14:11:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932576, encodeId=fbe219325e6a9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Sep 15 03:11:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701027, encodeId=b1371e01027c7, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Wed May 09 13:11:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252265, encodeId=337c12522659f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256572, encodeId=c95c12565e205, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540891, encodeId=6ea6154089122, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2069802, encodeId=df662069802fc, content=<a href='/topic/show?id=904282239db' target=_blank style='color:#2F92EE;'>#肺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82239, encryptionId=904282239db, topicName=肺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Sun Nov 26 14:11:00 CST 2017, time=2017-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932576, encodeId=fbe219325e6a9, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Sep 15 03:11:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701027, encodeId=b1371e01027c7, content=<a href='/topic/show?id=7113e15237a' target=_blank style='color:#2F92EE;'>#癌细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71523, encryptionId=7113e15237a, topicName=癌细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3fb930318282, createdName=hywen7336, createdTime=Wed May 09 13:11:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252265, encodeId=337c12522659f, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256572, encodeId=c95c12565e205, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540891, encodeId=6ea6154089122, content=<a href='/topic/show?id=ba2ee78630b' target=_blank style='color:#2F92EE;'>#细胞增殖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77863, encryptionId=ba2ee78630b, topicName=细胞增殖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f58613291856, createdName=晓辰, createdTime=Fri Jun 09 10:11:00 CST 2017, time=2017-06-09, status=1, ipAttribution=)]

相关资讯

CHEST:肺癌行机器人辅助肺叶切除术的效果

在这项研究中探讨了行肺叶切除术患者(pts)的肺部肿瘤的不对称性及结局。

Lancet Oncol:放疗与PD-L1抑制剂:携手共抗肺癌(KEYNOTE-001)

Lancet Oncology于5月23日在线发表了Shaverdian等人关于放疗联合pembrolizumab用于非小细胞肺癌治疗临床I期试验相关分析的文章,并配发了鲁汶大学医院Ruysscher的述评。检查点抑制剂用于转移性非小细胞肺癌(NSCLC)的一线及二线治疗,可以显着改善患者的无进展生存、总生存及生活质量。同时早已明确放疗也会活化免疫系统中与免疫治疗耐药相关的关键部分。很多癌症细胞并

剖析肺癌早期诊断的全球创新驱动力,梳理AI与液体活检的企业图谱及产品形态

在中国每年新增的73万肺癌患者中,王丽只是冰山一角。但是对于她的家人和她自己来说,她就是全部。从开始发病到最后的确诊,王丽用了三个月才确诊病情,这件事情一直被网友诟病。然而,肺癌的确诊真的那么难吗?

Nature杂志5月不得不看的亮点研究

不知不觉,5月份即将结束了,在即将过去的5月里Nature杂志又有哪些亮点研究值得学习呢?小编对此进行了整理,与各位一起学习。 【1】Nature:重磅!一些人胚胎干细胞系发生癌症相关突变 doi:10.1038/nature22312 根据一项新的研究,在用于基础研究或临床开发的140种人胚胎干细胞系当中,5种人胚胎干细胞系在肿瘤抑制基因TP53上获得突变。其中的两种人胚胎干细胞系H

ASCO:肺癌患者无进展生存期新药显著延长脑转移患者无进展生存期

阿斯利康今日报告了泰瑞沙(奥希替尼)针对非小细胞癌(NSCLC)患者出现中枢神经系统转移治疗的有效性,此前,泰瑞沙经证实将可能成为用于晚期或转移的EGFR T790M 阳性突变非小细胞肺癌成人患者新的标准治疗方案。此次在2017美国临床肿瘤学会(ASCO)年会上公布的数据与此前临床和临床前显示奥希替尼可穿透血脑屏障的发现一致。

肺癌二线治疗失败、耐药后,何去何从?

非小细胞肺癌(NSCLC)是肺癌中的主要病理类型,约占总体患者的80%以上。而半数以上的NSCLC患者在疾病诊断时已是局部晚期或已发生远处转移,无法进行手术切除,导致预后较差,美国2006年~2012年调查数据显示,这部分患者整体5年生存率仅为17.7%。 在当前NSCLC的临床实践中,三线治疗缺乏统一标准,使得治疗难度仍未降低,多线治疗的效果仍十分局限。因此,迫切需要探索疗效确切且安全性高的新